[go: up one dir, main page]

MA26673A1 - Composes pharmaceutiques - Google Patents

Composes pharmaceutiques

Info

Publication number
MA26673A1
MA26673A1 MA25728A MA25728A MA26673A1 MA 26673 A1 MA26673 A1 MA 26673A1 MA 25728 A MA25728 A MA 25728A MA 25728 A MA25728 A MA 25728A MA 26673 A1 MA26673 A1 MA 26673A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Application number
MA25728A
Other languages
English (en)
Inventor
Tolar Martin Michael
Holder Jurgensen Cynthia
Mary Daluge Susan
Howard Osterhout Martin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26673A1 publication Critical patent/MA26673A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA25728A 1998-08-13 1999-08-11 Composes pharmaceutiques MA26673A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9817623.3A GB9817623D0 (en) 1998-08-13 1998-08-13 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
MA26673A1 true MA26673A1 (fr) 2004-12-20

Family

ID=10837179

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25728A MA26673A1 (fr) 1998-08-13 1999-08-11 Composes pharmaceutiques

Country Status (36)

Country Link
US (3) US6608069B1 (fr)
EP (1) EP1104422B1 (fr)
JP (3) JP3631961B2 (fr)
KR (1) KR20010085369A (fr)
CN (2) CN1149215C (fr)
AP (1) AP1408A (fr)
AR (1) AR020154A1 (fr)
AT (1) ATE259810T1 (fr)
AU (1) AU775819B2 (fr)
BR (1) BR9913020A (fr)
CA (1) CA2340350A1 (fr)
CO (1) CO5130007A1 (fr)
DE (1) DE69914921T2 (fr)
DK (1) DK1104422T3 (fr)
EA (1) EA004139B1 (fr)
EE (1) EE04721B1 (fr)
ES (1) ES2215399T3 (fr)
GB (1) GB9817623D0 (fr)
HU (1) HUP0103637A3 (fr)
ID (1) ID28723A (fr)
IL (1) IL141318A0 (fr)
IS (1) IS5843A (fr)
MA (1) MA26673A1 (fr)
MY (1) MY133393A (fr)
NO (1) NO20010715L (fr)
NZ (1) NZ509778A (fr)
PE (1) PE20000952A1 (fr)
PL (1) PL346055A1 (fr)
PT (1) PT1104422E (fr)
SI (1) SI1104422T1 (fr)
SK (1) SK2222001A3 (fr)
TR (1) TR200100448T2 (fr)
TW (1) TWI224598B (fr)
WO (1) WO2000009507A1 (fr)
YU (1) YU11601A (fr)
ZA (1) ZA200101186B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6545007B2 (en) * 2000-11-17 2003-04-08 Idenix (Cayman) Limited Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines
ATE326225T1 (de) * 2001-02-28 2006-06-15 Smithkline Beecham Corp Xanthin-glycol-derivate zur behandlung des reizdarmsyndroms
EP1418882A1 (fr) 2001-08-24 2004-05-19 Unilever N.V. Composition orale comprenant un hydroxybenzoate d'alkyle
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
HU229504B1 (hu) 2001-11-09 2014-01-28 Gilead Sciences A2B-adenozinreceptor-antagonisták
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20040072848A1 (en) * 2002-02-26 2004-04-15 Huber Brian E Methods of treating irritable bowel syndrome and functional dyspepsia
AU2003231805A1 (en) 2002-06-17 2004-02-09 Glaxo Group Limited Purine derivatives as liver x receptor agonists
PT1658291E (pt) * 2003-08-25 2013-10-21 Dogwood Pharmaceuticals Inc 8-heteroarilxantinas substituídas
GB0324086D0 (en) * 2003-10-14 2003-11-19 Glaxo Group Ltd Process for preparing a co-precipitate of a non-crystalline solid drug substance
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US8318728B2 (en) 2008-05-14 2012-11-27 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009140519A1 (fr) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Composés et compositions pour le traitement de lésions induites par des agents de guerre chimique
WO2009140517A1 (fr) 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Composés et compositions pour le traitement de lésions induites par des agents de guerre chimique
MX2010012583A (es) * 2008-05-30 2011-02-24 Genentech Inc Compuestos inhibidores de purina pi3k y métodos de uso.
CN102260260B (zh) * 2010-05-24 2014-08-06 中国科学院上海药物研究所 8-苯基黄嘌呤类化合物、其制备方法、包含该化合物的药物组合物及其用途
CN102993203B (zh) * 2011-09-09 2015-11-25 温州医学院 8-苯基黄嘌呤类衍生物的制备及应用
US9502952B2 (en) 2012-10-12 2016-11-22 Persimmon Technologies, Corp. Hybrid motor
US9988399B2 (en) * 2013-05-10 2018-06-05 Gilead Apollo, Llc Bicyclic compounds as ACC inhibitors and uses thereof
CA2911818A1 (fr) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Inhibiteurs de l'acc et utilisations associees
MX2015015422A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
EP2994141A4 (fr) 2013-05-10 2016-11-23 Nimbus Apollo Inc Inhibiteurs de l'acc et utilisations associées
AU2023413736A1 (en) 2022-12-20 2025-06-26 Invios Gmbh Substituted 3,7-dihydro-1 h-purine-2,6-diones and use thereof
EP4389749A1 (fr) * 2022-12-20 2024-06-26 invIOs GmbH 3,7-dihydro-1h-purine-2,6-diones substituées et leur utilisation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442125A (en) * 1978-06-26 1984-04-10 Oxford Hill, Ltd. Process for detaching or preventing attachment of microorganisms to a surface
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5015647A (en) 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
GB8826595D0 (en) 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
TW252044B (fr) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
WO1995013094A1 (fr) * 1993-11-10 1995-05-18 Bristol-Myers Squibb Company Traitement des affections inflammatoires d'origine bacterienne
US5395831A (en) 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
WO1997034616A1 (fr) 1996-03-18 1997-09-25 Medical Science Systems, Inc. Procede de traitement des maladies du periodonte
ES2185837T3 (es) 1996-06-07 2003-05-01 Hoechst Ag Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de las enfermedades de choque, nuevos compuestos de xantina y procedimientos para su produccion.
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
AU2640999A (en) 1998-02-26 1999-09-15 Zenyaku Kogyo Kabushiki Kaisha 1-azaindolizine derivatives
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
IL150368A0 (en) 1999-12-23 2002-12-01 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
US20020006915A1 (en) * 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
US6751206B1 (en) 2000-06-29 2004-06-15 Qualcomm Incorporated Method and apparatus for beam switching in a wireless communication system

Also Published As

Publication number Publication date
IL141318A0 (en) 2002-03-10
PL346055A1 (en) 2002-01-14
KR20010085369A (ko) 2001-09-07
JP2002522542A (ja) 2002-07-23
AP2001002071A0 (en) 2001-03-31
AP1408A (en) 2005-05-06
DK1104422T3 (da) 2004-06-14
AR020154A1 (es) 2002-04-10
BR9913020A (pt) 2001-05-08
JP2004137251A (ja) 2004-05-13
NO20010715L (no) 2001-04-02
WO2000009507A1 (fr) 2000-02-24
AU5732399A (en) 2000-03-06
ATE259810T1 (de) 2004-03-15
EA200100127A1 (ru) 2001-10-22
JP3631961B2 (ja) 2005-03-23
ZA200101186B (en) 2002-02-12
EA004139B1 (ru) 2004-02-26
EE200100083A (et) 2002-06-17
DE69914921T2 (de) 2004-12-23
HUP0103637A2 (en) 2002-06-29
PT1104422E (pt) 2004-06-30
EE04721B1 (et) 2006-10-16
CN1149215C (zh) 2004-05-12
EP1104422A1 (fr) 2001-06-06
US6770267B2 (en) 2004-08-03
NZ509778A (en) 2003-08-29
PE20000952A1 (es) 2000-09-29
TWI224598B (en) 2004-12-01
MY133393A (en) 2007-11-30
US6608069B1 (en) 2003-08-19
SK2222001A3 (en) 2001-12-03
EP1104422B1 (fr) 2004-02-18
ID28723A (id) 2001-06-28
HK1035195A1 (en) 2001-11-16
TR200100448T2 (tr) 2001-09-21
US20030032804A1 (en) 2003-02-13
NO20010715D0 (no) 2001-02-12
CO5130007A1 (es) 2002-02-27
ES2215399T3 (es) 2004-10-01
JP2004115534A (ja) 2004-04-15
DE69914921D1 (en) 2004-03-25
SI1104422T1 (en) 2004-06-30
CN1251676C (zh) 2006-04-19
HUP0103637A3 (en) 2002-10-28
AU775819B2 (en) 2004-08-19
IS5843A (is) 2001-02-09
CA2340350A1 (fr) 2000-02-24
US20040034020A1 (en) 2004-02-19
YU11601A (sh) 2004-03-12
GB9817623D0 (en) 1998-10-07
CN1323309A (zh) 2001-11-21
CN1515571A (zh) 2004-07-28

Similar Documents

Publication Publication Date Title
MA26673A1 (fr) Composes pharmaceutiques
ID23299A (id) Formulasi-formulasi farmasi
DE69908021D1 (de) Ziprasidonhaltige Arzneimittel
ID27415A (id) Komposisi farmaseutik
NO20001776L (no) Medikamenter
NO20005913D0 (no) Legemiddelsammensetning
NO20005218D0 (no) Farmasøytisk aerosolpreparat
NO20010046D0 (no) Dolastatin-15-derivater
NO20005399L (no) Farmasöytisk preparat
NO996372L (no) Fast farmasøytisk preparat inneholdende benzofuanderivater
ID29089A (id) Sediaan farmasi moksifloksasin
DK1466615T3 (da) Farmaceutisk præparat
NO20015670D0 (no) Forbedrede farmasöytiske formuleringer
ID27201A (id) Komposisi farmasi
EP0850057A4 (fr) Composes pharmaceutiques
NO20022606L (no) Farmasöytiske kombinasjoner
ID27150A (id) Sediaan levotiroksin bahan farmasi
ATE309838T1 (de) Pharmazeutisches implantat
EP1087957A4 (fr) Composes auto-inducteurs
NO20014926D0 (no) Farmasöytiske forbindelser
FR2802423B1 (fr) Compositions pharmaceutiques
ID30032A (id) Formulasi farmasi
EP0923564A4 (fr) Composes pharmaceutiques
IS6163A (is) Lyfjakomplex
EP1124557A4 (fr) Composition pharmaceutique